I25 Stock Chart & Stats
€103.00
-€1.00(-1.16%)
At close: 4:00 PM EST
€103.00
-€1.00(-1.16%)
Day’s Range― - ―
52-Week Range€87.50 - €179.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.60B
Enterprise Value€3.83B
Total Cash (Recent Filing)€549.62M
Total Debt (Recent Filing)€729.29M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Jul 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding32,862,408
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€154.71Price Target Upside50.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€771.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~70% gross margins reflect durable product economics from the Zio device plus cloud reporting and scale. Margin strength, driven by manufacturing automation and clinical efficiencies, underpins the company’s ability to fund SG&A, R&D and supports the raised adjusted EBITDA guidance over the medium term.
Strong Revenue Growth And Guide RaiseDouble‑digit organic growth and an upward revision to full‑year guidance indicate broadening clinical adoption and commercial traction. Persistent prescription volume, enterprise deployments and EHR integration point to recurring episode-based revenue that should sustain top‑line expansion over several quarters.
Improving Cash Generation And Strong Cash BufferA shift from negative to positive operating cash flow and TTM free cash flow signals structural improvement in cash conversion. Combined with a large cash position disclosed at quarter end, this provides financial flexibility to invest in AI, international expansion and product R&D while reducing near‑term funding pressure.
Bears Say
High LeverageA debt‑heavy capital structure creates ongoing interest and refinancing risk that reduces strategic flexibility. High leverage makes the company more sensitive to execution setbacks or reimbursement headwinds, potentially constraining investment cadence or forcing tougher cost control if revenue growth slows.
Regulatory And Legal OverhangsOutstanding regulatory (FDA warning letter) and investigatory (DOJ CID) matters create multi‑quarter uncertainty around product approvals and commercialization scope. These risks can delay AI/510(k) rollouts, complicate payer discussions, and increase compliance costs, damping durable adoption momentum until resolved.
GAAP Net Losses PersistDespite margin expansion and positive operating cash flow, continued GAAP and adjusted net losses indicate the company has not fully converted operating improvements into sustained accounting profitability. Persistent losses can limit retained earnings, strain returns metrics and keep dilution or cost control as ongoing priorities.
Irhythm Technologies News
I25 FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was €87.50 and its highest was €179.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is €3.60B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Apr 30, 2026. The company reported -€0.376 earnings per share for the quarter, beating the consensus estimate of -€0.577 by €0.2.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.04.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,862,408 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -€0.376 in its last earnings report, beating expectations of -€0.577. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in DE:I25
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€154.71 (50.20% Upside)
€154.71 (50.20% Upside)
Blogger Sentiment
Bullish
DE:I25 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €594.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.14%
12-Months-Change
Fundamentals
Return on Equity
-20.60%
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
I25 Company Deck
I25 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was constructive and predominantly positive: the company delivered strong top-line growth (≈26% YoY), meaningful margin expansion (880 bps adjusted EBITDA improvement and +210 bps gross margin), raised full‑year revenue and EBITDA guidance, and showed progress on product, AI, clinical evidence, and international commercialization. Offsetting items include continued GAAP/adjusted net losses (though improved), seasonally negative Q1 free cash flow, elevated operating and litigation-related costs, and outstanding regulatory and legal uncertainties (FDA warning letter, DOJ CID) plus potential coverage ambiguity from proposed LCD language. On balance, the operational and commercial positives materially outweigh the remaining execution and regulatory risks.View all DE:I25 earnings summariesI25 Stock 12 Month Forecast
Average Price Target
€154.71
▲(50.20% Upside)
Technical Analysis
Options Prices
Currently, No data available
---